ClinicalTrials.gg
RecruitingNCT06441786Updated Sep 29, 2025

A Metacognitive Group Therapy of Depression and Anxiety in Youth With Autism

An interventional study of A metacognitive group therapy of depression and anxiety in youth with autism in Anxiety Depression, sponsored by Uppsala University. Recruiting at 1 site in Sweden. Open to participants aged 15 Years to 18 Years. Per ClinicalTrials.gov, last updated 2025-09-29.

Sponsored by Uppsala University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
15 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Depression by Uppsala University — 5 open to participants now, 5 under way, none of them phase 3. Depression · Uppsala University.

Planned enrollment
9th of 13
36 · median 60
Started
2024
with 3 others
No phase
12 of 17
4 open now
Registered
13th of 17
by date

Among the 17 studies in Depression by Uppsala University, this one is the 9th largest by planned enrollment of the 13 interventional ones that give a count, is one of 4 that started in 2024, is one of 12 with no phase, and was the 13th registered.

Depression

8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.

Browse Depression studies →

Open to participants now

5 of the 17 studies in Depression by Uppsala University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.

This study: 15 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Depression by Uppsala University, or all of them as a file.
02

Study summary

The goal of this open clinical trial is to try out and evaluate a group metacognitive treatment protocol, for adolescents aged 15-18 years of age with anxiety and/or depression and an autism diagnosis.

The main questions it aims to answer are:

  1. How does the recruitment to the study work and what is the retention rate?
  2. What is the level of participant compliance?
  3. Is the treatment adherence satisfactory, are there any practical problems with treatment delivery?
  4. Are the outcome measures and assessment procedures feasible?
  5. Do the participants accept the treatment, are there any reports of adverse effects?
  6. What are the preliminary effects of the treatment regarding

    1. Symptoms of anxiety and/or depression
    2. Quality of life
    3. Functional impairment
    4. Subjective level of stress
    5. Central metacognitive processes
  7. Are changes in metacognitive processes related to changes in anxiety and depression?

The participants will partake in metacognitive group treatment of 10 sessions following an initial screening.

Read the detailed description

Participants in the study are youth (15 to 18 years of age) seeking help for anxiety and depression within child and youth psychiatry. There will a consecutive inclusion to form 6 treatment groups with 6 persons in each. The groups will meet once every week. Assessments will take place at pre- and post-treatment as well as at 6-month follow-up. Some metacognitive processes will also be monitored at each group session. The therapists have undergone a specialist training in metacognitive therapy and are experienced in using the methods. The main focus of the study is on feasibility, acceptability and preliminary effects of the treatment. These will be analyzed with paired sample t-test on primary and secondary outcomes.

03

Conditions studied

  • Anxiety Depression

Browse trials for

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 15 to 18 years
  • Seeking medical care PRIMA psychiatric clinic for children and youth in Stockholm
  • Diagnoses of anxiety disorder or depression as well as autism established in a clinical interview
  • Mastering the Swedish language enough to take part of the treatment
  • Willingness/ability to participate after receiving information about what participation entails

Exclusion criteria

Exclusion Criteria:

  • Assessed to meet one of the following diagnoses: Bipolar syndrome, alcohol use syndrome, substance use syndromes, psychotic symptoms and affective syndromes with psychotic symptoms and antisocial personality disorder.
  • Assessed to have a high suicide risk.
  • Assessed to have extensive self-harm behavior or moderate to high risk of such.
  • Participating in other psychological treatment or about to start such treatment during the time interval of the study.
  • Has not had stable medication in the last month or is planning a deposit/medication adjustment during the time interval of the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    A metacognitive group therapy of depression and anxiety in youth with autism

    A within group design where one clinical manualized intervention, Metacognitive therapy (MCT) for anxiety and depression, is offered in a 10-session group format to adolescents. The therapists have received special training in MCT and are experienced in using the methods. The treatment is delivered face-to-face.

    Behavioral: A metacognitive group therapy of depression and anxiety in youth with autism

Interventions

  • BehavioralA metacognitive group therapy of depression and anxiety in youth with autism

    The treatment model is based on Adrian Wells' transdiagnostic A-M-C model and treatment structure described in Wells (2009) "Metacognitive therapy for anxiety and depression". The group treatment is delivered in 10 weekly sessions.

06

What researchers measure

Primary outcomes

  1. Revised Children's Anxiety and Depression Scale (RCADS)

    A self-report that measures symptoms of anxiety and depression.

    Time frame: Change from pre intervention to treatment completion at 10 weeks and at a 6 month follow-up

Secondary outcomes

  1. Brunnsviken Brief Quality of life questionnaire (BBQ)

    Measure of quality of life with a total score ranging from 0 to 96 with a higher score indicating a higher quality of life. The scores of each of the six primary questions regarding perceived quality of life within an area of life are multiplied with the score of an item measuring the perceived importance of the area in question.

    Time frame: Change from pre intervention to treatment completion at 10 weeks and at a 6 month follow-up

  2. Metacognitions Questionnaire - 30 items version (MCQ-30)

    A self-report measuring metacognitive assumptions and processes.

    Time frame: Change from pre intervention to treatment completion at 10 weeks and at a 6 month follow-up

  3. Cognitive Attentional Syndrome Scale (CAS-1)

    A self-report measuring the presence of Cognitive Attentional Syndrome

    Time frame: Change from pre intervention to treatment completion at 10 weeks and at a 6 month follow-up

  4. Child Sheehan Disability Scale (CSDS)

    A subjective appraisal of functional impairment related to familial, social and vocational aspects of life.

    Time frame: Change from pre intervention to treatment completion at 10 weeks and at a 6 month follow-up

  5. Perceived Stress Scale 10 (PSS-10)

    A questionnaire that aims to measure symptoms of stress. It contains 10 items that are scored on a range between 0 (never) to 4 (very often). The total score range is between 0-40 and a higher score reflects higher levels of perceived stress.

    Time frame: Change from pre intervention to treatment completion at 10 weeks and at a 6 month follow-up.

Other outcomes

  1. Negative Effects Questionnaire, 20 items Child (NEQ 20C)

    A self-report measuring negative effects of the treatment and some aspects related to acceptability.

    Time frame: After treatment completion at 10 weeks.

07

Study locations

1 of 1 sites recruiting
  • PRIMA Child and Youth Psychiatry, Handen
    Haninge, Stockholm County 13640, Sweden
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2024 (actual). Primary completion is estimated for Aug 2026, 24 months after the start.

Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is above that.

Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.

How these figures are worked out, and which studies are left out of them.

Registered
May 28, 2024
First posted
Jun 4, 2024
StartActual
Aug 12, 2024
Primary completionEst.
Aug 29, 2026
CompletionEst.
Aug 29, 2026
Last update
Sep 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06441786
Lead sponsor
Uppsala University
Responsible party
Sponsor
First posted
Jun 4, 2024
Start date
Aug 12, 2024
Primary completion
Aug 29, 2026 (estimated)
Completion
Aug 29, 2026 (estimated)
Last update
Sep 29, 2025

Study contacts

Timo Hursti, Ph.D.
Contact
timo.hursti@psyk.uu.se
46 184717842
Timo Hursti, Ph.D.
principal investigator · Uppsala University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion